Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Durvillaea antarctica

ABSTRACT: Durvillaea antarctica overview

PROVIDER: PRJNA980328 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR6123260_1.fastq.gz	Fastqsanger.gz
	SRR6123260_2.fastq.gz	Fastqsanger.gz
	SRR6123270_1.fastq.gz	Fastqsanger.gz
	SRR6123270_2.fastq.gz	Fastqsanger.gz
	SRR6123280_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 334

Similar Datasets

Durvillaea antarctica

Project description:Durvillaea antarctica Genome sequencing and assembly

| PRJNA979950 | ENA

Durvillaea antarctica

Project description:Durvillaea antarctica (southern bull-kelp) GBS data

| PRJNA412568 | ENA

A β-1,3/1,6-glucan from Durvillaea Antarctica enhances anti-tumor effects of immune checkpoint inhibitor antibodies

Project description:Immunotherapy has emerged as a frontline approach in cancer management, aiming to enhance the adaptive immune response against tumors. However, its limited efficacy across a narrow range of tumor types necessitates the exploration of novel strategies that target innate immunity. Therapeutic modulation of pattern recognition receptors (PRRs) and innate immune cells holds promise in tumor eradication. β-glucan, a pathogen-associated molecular pattern (PAMP), acts as an immunostimulator, bridging the innate and adaptive immune responses. It exhibits low toxicity and high compatibility with various antitumor strategies. Plenty of clinical trials are ongoing to evaluate β-glucan-based cancer immunotherapy and shows promising clinical benefits across multiple cancer types. A soluble β-1,3/1,6-glucan with high purity from Durvillaea Antarctica (BG136) was reported previously by our group to exhibit pan antitumor effects alone as an immune stimulator. In current study, we proved the antitumor activity of BG136 in combination with anti-PD-1 antibodies in MC38 syngeneic tumor model in vivo. Integrated transcriptomic and metabolomic analyses suggest that BG136 enhances the antitumor immunity of anti-PD-1 antibodies by reprogramming tumor microenvironment to more proinflammatory status. There are more innate and adaptive immune cell infiltration and activation, enhanced lipid metabolism, decreased ascorbate and aldarate metabolism. These findings provide mechanistic insights supporting the potent antitumor efficacy of BG136 in combination with immune checkpoint inhibitor antibodies.

2024-12-31 | GSE241125 | GEO

A β-1,3/1,6-glucan from Durvillaea Antarctica enhances anti-tumor effects of immune checkpoint inhibitor antibodies II

2024-12-31 | GSE242577 | GEO

Expression analysis of Pseudozyma antarctica T-34 and Ustilago maydis on different carbon source

Project description:Investigation of whole genome gene expression level in Pseudozyma antarctica T-34, compared to Ustilago maydis UM521. To clarify the transcriptomic characteristics of Pseudozyma antarctica under the conditions of high MEL production, a DNA microarray of both the strains, Pseudozyma antarctica T-34 and Ustilago maydis UM521 was prepared and analyzed the transcriptomes.

2014-03-21 | GSE47171 | GEO

Response of Phaeocystis antarctica under changing iron conditions

Project description:The study aims at deciphering the response of Phaeocystis antarctica under iron limitation and iron supplementation at a transcriptomic level.

2018-12-15 | GSE102608 | GEO

Expression analysis of Pseudozyma antarctica T-34 and Ustilago maydis on different carbon source

2014-03-21 | E-GEOD-47171 | biostudies-arrayexpress

Durvillaea antarctica

Project description:Lessonia nigrescens genome sequencing and assembly

| PRJNA979832 | ENA

Deschampsia antarctica

Project description:Deschampsia antarctica overview

| PRJNA160353 | ENA

Gondogeneia antarctica

Project description:Gondogeneia antarctica overview

| PRJNA77185 | ENA